Role of Custom Antibodies in Neurological Disorders the way that scientists study and treat neurological disorders. Oncimmune’s autoantibody profiling platform allows for a comprehensive analysis of the immune system’s role in these conditions by measuring antibodies against a wide range of proteins expressed in the nervous system with a single test. The article explores how this approach can be tailored to specific research applications, using a neurological focused antigen array and other specialized antibodies as examples.

Antibody Functionality

While mAbs have revolutionized therapy by targeting disease processes, they often trigger immune-mediated adverse reactions in humans. These AEs can be unpredictable and may not always be correlated with antigen recognition. Nonetheless, their frequent occurrence and significant impact on treatment outcomes warrant careful risk management.

To minimize the potential for AEs, it is important to select antibodies with high affinity and specificity. Various methods can improve antibody binding to particular targets, including protein engineering techniques that alter the architecture of antibody structures (e.g., scaffold optimization and domain interface engineering). These techniques enhance an antibody’s capacity to identify challenging antigens.

Bispecific antibodies can significantly improve therapeutic efficiency by allowing them to recognize and bind two different antigens simultaneously. This feature makes them useful for directing effector cells to target cells, delivering ligands to specific cell populations, simultaneously blocking two pathways, and promoting shuttling across biological barriers (e.g., through the blood-brain barrier).